stockportfolio.pro
Stocks / KYTX vs SRTA
KYTX vs SRTA
Kyverna Therapeutics, Inc. and Strata Critical Medical, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Kyverna Therapeutics, Inc. (KYTX) | Strata Critical Medical, Inc. (SRTA) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $0 | $197.14M |
| Net income (latest FY) | $-161.31M | $41.35M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | 21.0% |
| Return on equity | -69.4% | 14.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open KYTX — free Open SRTA — freeFrequently asked questions
Which is bigger, KYTX or SRTA?
Kyverna Therapeutics, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, KYTX or SRTA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.